Medium materiality6/10
Monte Rosa Therapeutics price target lowered at Jefferies after Novo trial miss
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Jefferies lowers GLUE target to $25; current price around $16.52; upside remains.
- Jefferies lowers GLUE target to $25
- GLUE upside remains above price
Key facts
- 01
Target: $25
- 02
Posted price: $16.52
- 03
Analyst firm: Jefferies
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.